Background
Our client had an asset in early development for a neurology indication but wanted to understand which other indications in the neuroscience space would be most suitable, have the biggest unmet need, and produce the largest commercial success.
Valid Insight were asked to assess the commercial opportunity of ten potential indications. The results of this assessment would be utilised internally across the early asset pipeline and the neuroscience environment to support research & development. Importantly, the client wanted clear recommendations on where their asset could be best utilised to support cross-functional internal decision-making.
Approach
We utilised a three-way approach to determine the indications of value:
- Secondary research, which identified several factors including epidemiology, patient segmentation, clinical and economic burden for each of the indications.
- Primary research with payers, KOLs and patient advocacy groups, which tested the target product profile, assumptions on cost-effectiveness, unmet need, current and future landscape, evaluation of the price, and the reimbursement landscape.
- Net Present Value and Monte Carlo modelling to support the commercial understanding of opportunity across the product lifecycle.
Results
The client had a clear understanding and ranking of the recommended indications for launch, including details of the commercial potential for the asset in each indication.
This allowed for internal alignment on the asset and launch indications, and allowed the client to make informed, critical internal decisions, planning clinical development programs to support launch in selected indications.